Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma
Open Access
- 7 March 2017
- journal article
- review article
- Published by Taylor & Francis in OncoImmunology
- Vol. 6 (8) , e1299303
Abstract
Existing clinical, anatomopathological and molecular biomarkers fail to reliably predict the prognosis of cutaneous melanoma. Biomarkers for determining which patients receive adjuvant therapies are needed. The emergence of new technologies and the discovery of new immune populations with different prognostic values allow the immune network in the tumor to be better understood. Importantly, new molecules identified and expressed by immune cells have been shown to reduce the antitumor immune efficacy of therapies, prompting researchers to develop antibodies targeting these so-called “immune checkpoints”, which have now entered the oncotherapeutic armamentarium.Keywords
This publication has 139 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanomaNature Genetics, 2012
- A Landscape of Driver Mutations in MelanomaCell, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Overall survival and PD‐L1 expression in metastasized malignant melanomaCancer, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell developmentProceedings of the National Academy of Sciences, 2006